Loading
A phase 3 trial of Trastuzumab and Trastuzumab biosimilars in Ductal carcinoma in situ, run by National Cancer Institute (NCI), completed.
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy is a phase 3 interventional study registered as NCT00769379 by National Cancer Institute (NCI), with 2014 participants recorded, started 2008-12-10 and reaching its primary completion in 2019-12-31. Interventions recorded: Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation. Conditions recorded: Breast Ductal Carcinoma In Situ.
Linked to the drug Trastuzumab biosimilars because the registry names it among its interventions and Ductal carcinoma in situ among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
2,014 enrolled.
95% CI 93.8 to 96.5; Figures from the ClinicalTrials.gov results section (first posted 2022-02-23), not from a publication · 95% CI 94.9 to 97.3
Source95% CI 98.2 to 99.5; Figures from the ClinicalTrials.gov results section (first posted 2022-02-23), not from a publication · 95% CI 98.3 to 99.6
SourceShares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
Shares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
Shares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
Shares Trastuzumab and the tag pipeline.
Shares Trastuzumab and the tag pipeline.
Shares Trastuzumab and the tag pipeline.
Shares Trastuzumab and the tag pipeline.
Shares Trastuzumab and the tag pipeline.